PCI Pharma Services Reaches 80 Serialization Installations

Company’s seven-plus-year preparedness for global product security requirements meets multiple standards worldwide, enabling biopharma customers to provide safe and effective medication supplies.

Biopharmaceutical services provider PCI Pharma Services is celebrating the protection of global drug products with the installation of its 80th serialization line.

The company provides product security for global medicines through advanced serialization and anti-counterfeiting technologies, investing heavily in services advancing the commercialization of therapies destined to domestic and global markets, supporting medicines destined to more than 100 countries around the world.

PCI’s preparedness for global product security requirements has spanned more than seven years, with support for products meeting the U.S. Drug Supply Chain Security Act (DSCSA), European Union’s Falsified Medicines Directive (FMD), as well as in-country requirements in emerging markets including South Korea, Russia, China, Brazil, Saudi Arabia, and Turkey.

PCI’s architecture enables clients to gain singular connectivity to access the entirety of PCI’s global supply network in delivering serialized medicines with integrated overt and covert anti-counterfeiting protection features.

“It’s been a long journey” notes Brad Payne, PCI’s Senior Vice President of Global Operations. “At the earliest stages of our preparedness, we leveraged our knowledge and looked to implement a strategy that focused on the industry-leading experience for our customers, pairing the best technologies while maximizing ease of use, all with an eye towards allowing for scalability—knowing that at some point we would see the market finally reach maturity in terms of firm governmental requirements and a common framework. 

“Considerable credit needs to be given to organizations like GS1 for the work they have done in working to develop some market standards. The industry still has a ways to go in coalescing around a truly common standard, but PCI has been able to leverage an adaptable solution that allows us to meet the requirements of established markets as well as those countries still in flux with shifting or developing standards. The biopharmaceutical industry is truly a global business and we are helping clients meet the requirements for all markets around the world, ensuring safe and effective supplies of life-saving medicines for all patients.”

More in Home